Clinical trials
Memory Disorders trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Monica Triviño Mosquera | 2 |
| AB Science | 1 |
| AbbVie | 1 |
| Acumen Pharmaceuticals | 1 |
| Avraham Pharmaceuticals Ltd | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| Greece 2021 Committee | 1 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1 |
| Madrid Salud | 1 |
| Novartis Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Memory Disorders | 13 |
| Alzheimer Disease | 8 |
| Cognitive Dysfunction | 6 |
| Dementia | 6 |
| Nervous System Diseases | 3 |
| Neurodegenerative Diseases | 3 |
| Brain Diseases | 2 |
| Central Nervous System Diseases | 2 |
| Neurocognitive Disorders | 2 |
| Tauopathies | 2 |
Trials
Showing 51 to 13 of 13. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.